BioArctic announces research collaboration with Eisai regarding BAN2401 December 17, 2019 15:59 Regulatory Read more
BioArctic’s partner Eisai presents data from the ongoing BAN2401 Phase 2b extension study in early Alzheimer’s disease December 5, 2019 20:15 Regulatory Read more
BioArctic announces results from interim analysis of the Phase 1/2 study of SC0806 in patients with complete spinal cord injury November 18, 2019 22:30 Regulatory Read more
BioArctic presents Nomination Committee and publishes financial calendar 2020 November 5, 2019 08:00 Regulatory Read more
BioArctic receives MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s Disease May 20, 2019 17:45 Regulatory Read more
BioArctic’s partner Eisai initiates the confirmatory Phase 3 study of BAN2401 in early Alzheimer’s Disease March 22, 2019 00:40 Regulatory Read more
BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease March 13, 2019 22:30 Regulatory Read more
BioArctic: Eisai announces timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer’s disease March 7, 2019 08:45 Regulatory Read more
BioArctic’s product candidate SC0806 for treatment of patients with complete spinal cord injury is now in Phase 2 February 13, 2019 08:00 Regulatory Read more
BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Application for ABBV-0805 February 11, 2019 17:00 Regulatory Read more
BioArctic announces that Eisai will initiate Phase 3 confirmatory study with BAN2401 in early Alzheimer’s Disease February 4, 2019 10:00 Regulatory Read more
